Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Monteleone

Showing results (1-10 of 384) with videos related to

Pageof 39
Sort By:
Journal of Biomedicine & Biotechnology|July 24, 2010
Interleukin-21: a new mediator of inflammation in systemic lupus erythematosusMassimiliano Sarra, Giovanni Monteleone
Frontiers in Pharmacology|April 30, 2021
Precision Medicine in Inflammatory Bowel DiseasesIrene Marafini, Giovanni Monteleone
Current Opinion in Investigational Drugs (London, England : 2000)|May 25, 2007
Drug evaluation: TA-2711E in the treatment of active distal ulcerative colitisGiovanni Monteleone, Flavio Caprioli
Biologics : Targets & Therapy|July 2, 2020
Therapeutic Oligonucleotides for Patients with Inflammatory Bowel DiseasesIrene Marafini, Giovanni Monteleone
Clinical Science (London, England : 1979)|March 31, 2010
T-cell-directed therapies in inflammatory bowel diseasesGiovanni Monteleone, Flavio Caprioli
The New England Journal of Medicine|June 18, 2015
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's DiseaseGiovanni Monteleone, Francesco Pallone
Pharmaceutics|January 21, 2023
Smad7 Antisense Oligonucleotide in Crohn's Disease: A Re-Evaluation and Explanation for the Discordant Results of Clinical TrialsGiovanni Monteleone, Carmine Stolfi
United European Gastroenterology Journal|July 1, 2023
Smoking and colorectal cancer in inflammatory bowel disease: Quantity matters?Irene Marafini, Giovanni Monteleone
The Journal of Pathology|December 21, 2022
CDT1 drives replication overlicensing and enhances tumorigenesis in the gut<sup>†</sup>Giovanni Monteleone, Carmine Stolfi
Journal of Crohn'S & Colitis|March 28, 2020
Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection?Giovanni Monteleone, Sandro Ardizzone
Pageof 39

Showing results (1-10 of 384) with videos related to

Sort By:
Pageof 39
Journal of Biomedicine & Biotechnology|July 24, 2010
Interleukin-21: a new mediator of inflammation in systemic lupus erythematosusMassimiliano Sarra, Giovanni Monteleone
Frontiers in Pharmacology|April 30, 2021
Precision Medicine in Inflammatory Bowel DiseasesIrene Marafini, Giovanni Monteleone
Current Opinion in Investigational Drugs (London, England : 2000)|May 25, 2007
Drug evaluation: TA-2711E in the treatment of active distal ulcerative colitisGiovanni Monteleone, Flavio Caprioli
Biologics : Targets & Therapy|July 2, 2020
Therapeutic Oligonucleotides for Patients with Inflammatory Bowel DiseasesIrene Marafini, Giovanni Monteleone
Clinical Science (London, England : 1979)|March 31, 2010
T-cell-directed therapies in inflammatory bowel diseasesGiovanni Monteleone, Flavio Caprioli
The New England Journal of Medicine|June 18, 2015
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's DiseaseGiovanni Monteleone, Francesco Pallone
Pharmaceutics|January 21, 2023
Smad7 Antisense Oligonucleotide in Crohn's Disease: A Re-Evaluation and Explanation for the Discordant Results of Clinical TrialsGiovanni Monteleone, Carmine Stolfi
United European Gastroenterology Journal|July 1, 2023
Smoking and colorectal cancer in inflammatory bowel disease: Quantity matters?Irene Marafini, Giovanni Monteleone
The Journal of Pathology|December 21, 2022
CDT1 drives replication overlicensing and enhances tumorigenesis in the gut<sup>†</sup>Giovanni Monteleone, Carmine Stolfi
Journal of Crohn'S & Colitis|March 28, 2020
Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection?Giovanni Monteleone, Sandro Ardizzone
Pageof 39